Pacira Pharmaceuticals, Inc. Announces sNDA Submission for EXPAREL Nerve Block Indication

[Business Wire] – Pacira Pharmaceuticals, Inc. today announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration for a nerve block indication for EXPAREL® . more

View todays social media effects on PCRX

View the latest stocks trending across Twitter. Click to view dashboard

See who Pacira is hiring next, click here to view